GFR-话题@MedSci

#GFR#

483篇内容 | 2475人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1534220, encodeId=b67e1534220bf, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Lancet Oncol：EGFR野生型NSCLC二线治疗：厄洛替尼不敌标准化疗（TAILOR研究）, objectType=article, longId=26016, objectId=35c626016f7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=35c626016f7, replyNumber=0, likeNumber=55, createdTime=2013-11-01, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=35c626016f7, moduleTitle=Lancet Oncol：EGFR野生型NSCLC二线治疗：厄洛替尼不敌标准化疗（TAILOR研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=35c626016f7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534219, encodeId=195f1534219db, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=WCLC 2013：EGFR野生型NSCLC二线治疗中培美曲塞优于吉非替尼（CTONG 0806研究）, objectType=article, longId=26015, objectId=e591260152f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e591260152f, replyNumber=0, likeNumber=72, createdTime=2013-11-01, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e591260152f, moduleTitle=WCLC 2013：EGFR野生型NSCLC二线治疗中培美曲塞优于吉非替尼（CTONG 0806研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e591260152f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534218, encodeId=beeb15342189e, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Cell：EGFR通过beclin 1抑制自噬，诱导非小细胞肺癌生长和耐药, objectType=article, longId=24907, objectId=485e2490e1f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=485e2490e1f, replyNumber=0, likeNumber=67, createdTime=2013-09-26, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=485e2490e1f, moduleTitle=Cell：EGFR通过beclin 1抑制自噬，诱导非小细胞肺癌生长和耐药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=485e2490e1f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534217, encodeId=a4ca153421e7c, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Clin Lung Cancer：山东大学赵小刚等发现EGFR基因突变状态与非小细胞肺癌患者的一线化疗反应相关, objectType=article, longId=23996, objectId=dbe023996d4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dbe023996d4, replyNumber=0, likeNumber=59, createdTime=2013-09-08, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dbe023996d4, moduleTitle=Clin Lung Cancer：山东大学赵小刚等发现EGFR基因突变状态与非小细胞肺癌患者的一线化疗反应相关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dbe023996d4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534216, encodeId=e1e015342162b, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Ann Thorac Surg：EGFR 突变状态影响I期非小细胞肺癌患者的预后, objectType=article, longId=23948, objectId=a56b23948ef, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a56b23948ef, replyNumber=0, likeNumber=88, createdTime=2013-09-07, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a56b23948ef, moduleTitle=Ann Thorac Surg：EGFR 突变状态影响I期非小细胞肺癌患者的预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a56b23948ef)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534215, encodeId=c2db15342154b, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=PNAS：TNFSF15下调VEGFR1抑制血管内皮祖细胞新生血管, objectType=article, longId=22729, objectId=550522e2957, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=550522e2957, replyNumber=0, likeNumber=79, createdTime=2013-08-09, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=550522e2957, moduleTitle=PNAS：TNFSF15下调VEGFR1抑制血管内皮祖细胞新生血管, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=550522e2957)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534214, encodeId=7f8e1534214d4, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=AIM：柏林倡议研究（BIS）方程可能较肾小球滤过率（GFR）评估老年人肾功更**, objectType=article, longId=22194, objectId=b9062219477, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b9062219477, replyNumber=0, likeNumber=68, createdTime=2013-07-29, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b9062219477, moduleTitle=AIM：柏林倡议研究（BIS）方程可能较肾小球滤过率（GFR）评估老年人肾功更**, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b9062219477)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534213, encodeId=ae59153421367, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=FDA批准勃林格殷格翰旗下阿法替尼用于EGFR基因突变晚期NSCLC治疗, objectType=article, longId=21404, objectId=a78921404a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a78921404a7, replyNumber=0, likeNumber=58, createdTime=2013-07-17, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a78921404a7, moduleTitle=FDA批准勃林格殷格翰旗下阿法替尼用于EGFR基因突变晚期NSCLC治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a78921404a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534212, encodeId=f4141534212a0, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=PNAS：FGFR4 ，MAP3K9和PAK5可能成为非小细胞肺癌（NSCLC）的潜在治疗靶点, objectType=article, longId=21322, objectId=2d5c21322c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2d5c21322c6, replyNumber=0, likeNumber=66, createdTime=2013-07-14, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2d5c21322c6, moduleTitle=PNAS：FGFR4 ，MAP3K9和PAK5可能成为非小细胞肺癌（NSCLC）的潜在治疗靶点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2d5c21322c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534211, encodeId=d1641534211f8, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=JCO：阿法替尼可显著改善EGFR阳性晚期肺腺癌患者症状及生活质量, objectType=article, longId=21045, objectId=fd8c21045f7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fd8c21045f7, replyNumber=0, likeNumber=75, createdTime=2013-07-11, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fd8c21045f7, moduleTitle=JCO：阿法替尼可显著改善EGFR阳性晚期肺腺癌患者症状及生活质量, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fd8c21045f7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534210, encodeId=f85c153421049, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=ACIEE：针对非小细胞肺癌EGFRT790M突变体的靶向化合物被设计, objectType=article, longId=21032, objectId=41df210325e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=41df210325e, replyNumber=0, likeNumber=62, createdTime=2013-07-10, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=41df210325e, moduleTitle=ACIEE：针对非小细胞肺癌EGFRT790M突变体的靶向化合物被设计, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=41df210325e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534209, encodeId=c85215342099f, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Lung Cancer：EGFR突变与癌症家族史有密切关系, objectType=article, longId=20234, objectId=82b8202345e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=82b8202345e, replyNumber=0, likeNumber=80, createdTime=2013-06-20, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=82b8202345e, moduleTitle=Lung Cancer：EGFR突变与癌症家族史有密切关系, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=82b8202345e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534208, encodeId=cab5153420860, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=ASCO 2013：培美曲塞二线治疗EGFR野生型NSCLC优于吉非替尼, objectType=article, longId=19770, objectId=349119e7046, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=349119e7046, replyNumber=0, likeNumber=55, createdTime=2013-06-08, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=349119e7046, moduleTitle=ASCO 2013：培美曲塞二线治疗EGFR野生型NSCLC优于吉非替尼, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=349119e7046)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534207, encodeId=709c153420e45, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=ASCO 2013：两种药物治疗EGFR突变的晚期NSCLC的疗效对比, objectType=article, longId=19644, objectId=ac601964455, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ac601964455, replyNumber=0, likeNumber=81, createdTime=2013-06-06, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ac601964455, moduleTitle=ASCO 2013：两种药物治疗EGFR突变的晚期NSCLC的疗效对比, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ac601964455)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534206, encodeId=ca6c1534206b9, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=JCO：香港中文大学莫树锦对比分析EGFR TKI药物一二线治疗情况, objectType=article, longId=19401, objectId=650819401a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=650819401a2, replyNumber=0, likeNumber=94, createdTime=2013-05-30, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=650819401a2, moduleTitle=JCO：香港中文大学莫树锦对比分析EGFR TKI药物一二线治疗情况, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=650819401a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534205, encodeId=beec153420515, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=晚期非小细胞肺癌EGFR-TKI失败后治疗策略, objectType=article, longId=19179, objectId=ca42191e93e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ca42191e93e, replyNumber=0, likeNumber=65, createdTime=2013-05-24, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ca42191e93e, moduleTitle=晚期非小细胞肺癌EGFR-TKI失败后治疗策略, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ca42191e93e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534204, encodeId=9aa215342041a, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=ASCO 2013：香港中文大学莫树锦等证实pEGFR mut能有效预测非小细胞肺癌患者的预后, objectType=article, longId=19176, objectId=124a191e6be, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=124a191e6be, replyNumber=0, likeNumber=82, createdTime=2013-05-24, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=124a191e6be, moduleTitle=ASCO 2013：香港中文大学莫树锦等证实pEGFR mut能有效预测非小细胞肺癌患者的预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=124a191e6be)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534203, encodeId=77c015342035b, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=ASCO 2013：阿法替尼能显著改善EGFR突变阳性的亚裔NSCLC患者生活质量评分, objectType=article, longId=19047, objectId=7b791904e5b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7b791904e5b, replyNumber=0, likeNumber=85, createdTime=2013-05-23, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7b791904e5b, moduleTitle=ASCO 2013：阿法替尼能显著改善EGFR突变阳性的亚裔NSCLC患者生活质量评分, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7b791904e5b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534202, encodeId=d23b153420214, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=ASCO2013年会：EGFR野生的NSCLC人群中泰索帝疗效优于特罗凯, objectType=article, longId=18976, objectId=8b94189e681, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8b94189e681, replyNumber=0, likeNumber=67, createdTime=2013-05-22, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8b94189e681, moduleTitle=ASCO2013年会：EGFR野生的NSCLC人群中泰索帝疗效优于特罗凯, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8b94189e681)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534201, encodeId=4106153420127, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Ann Oncol：厄洛替尼可改善EGFR突变呈阳性的晚期NSCLC患者生活质量, objectType=article, longId=16121, objectId=a3fc16121f5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a3fc16121f5, replyNumber=0, likeNumber=0, createdTime=2013-03-17, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a3fc16121f5, moduleTitle=Ann Oncol：厄洛替尼可改善EGFR突变呈阳性的晚期NSCLC患者生活质量, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a3fc16121f5)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

GFR

2020-05-29

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Lancet Oncol：EGFR野生型NSCLC二线治疗：厄洛替尼不敌标准化疗（TAILOR研究）

2013-11-01

liuyiping (审核中...)

前往app查看评论内容

#GFR#

WCLC 2013：EGFR野生型NSCLC二线治疗中培美曲塞优于吉非替尼（CTONG 0806研究）

2013-11-01

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Cell：EGFR通过beclin 1抑制自噬，诱导非小细胞肺癌生长和耐药

2013-09-26

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Clin Lung Cancer：山东大学赵小刚等发现EGFR基因突变状态与非小细胞肺癌患者的一线化疗反应相关

2013-09-08

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Ann Thorac Surg：EGFR 突变状态影响I期非小细胞肺癌患者的预后

2013-09-07

liuyiping (审核中...)

前往app查看评论内容

#GFR#

PNAS：TNFSF15下调VEGFR1抑制血管内皮祖细胞新生血管

2013-08-09

liuyiping (审核中...)

前往app查看评论内容

#GFR#

AIM：柏林倡议研究（BIS）方程可能较肾小球滤过率（GFR）评估老年人肾功更**

2013-07-29

liuyiping (审核中...)

前往app查看评论内容

#GFR#

FDA批准勃林格殷格翰旗下阿法替尼用于EGFR基因突变晚期NSCLC治疗

2013-07-17

liuyiping (审核中...)

前往app查看评论内容

#GFR#

PNAS：FGFR4 ，MAP3K9和PAK5可能成为非小细胞肺癌（NSCLC）的潜在治疗靶点

2013-07-14

liuyiping (审核中...)

前往app查看评论内容

#GFR#

JCO：阿法替尼可显著改善EGFR阳性晚期肺腺癌患者症状及生活质量

2013-07-11

liuyiping (审核中...)

前往app查看评论内容

#GFR#

ACIEE：针对非小细胞肺癌EGFRT790M突变体的靶向化合物被设计

2013-07-10

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Lung Cancer：EGFR突变与癌症家族史有密切关系

2013-06-20

liuyiping (审核中...)

前往app查看评论内容

#GFR#

ASCO 2013：培美曲塞二线治疗EGFR野生型NSCLC优于吉非替尼

2013-06-08

liuyiping (审核中...)

前往app查看评论内容

#GFR#

ASCO 2013：两种药物治疗EGFR突变的晚期NSCLC的疗效对比

2013-06-06

liuyiping (审核中...)

前往app查看评论内容

#GFR#

JCO：香港中文大学莫树锦对比分析EGFR TKI药物一二线治疗情况

2013-05-30

liuyiping (审核中...)

前往app查看评论内容

#GFR#

晚期非小细胞肺癌EGFR-TKI失败后治疗策略

2013-05-24

liuyiping (审核中...)

前往app查看评论内容

#GFR#

ASCO 2013：香港中文大学莫树锦等证实pEGFR mut能有效预测非小细胞肺癌患者的预后

2013-05-24

liuyiping (审核中...)

前往app查看评论内容

#GFR#

ASCO 2013：阿法替尼能显著改善EGFR突变阳性的亚裔NSCLC患者生活质量评分

2013-05-23

liuyiping (审核中...)

前往app查看评论内容

#GFR#

ASCO2013年会：EGFR野生的NSCLC人群中泰索帝疗效优于特罗凯

2013-05-22

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Ann Oncol：厄洛替尼可改善EGFR突变呈阳性的晚期NSCLC患者生活质量

2013-03-17

科室
- - 订阅+
  - 更多科室
工具
服务